CRON241018C500
- 1.70
- 0.000.00%
Cronos Group Newsroom
Cronos Group: Caution Advised Amid Regulatory Uncertainties and Sector Re-rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)
Jefferies Remains a Hold on Cronos Group (CRON)
CIBC: Maintaining the Cronos Group (CRON.US) rating, adjusted from Outperformer to Outperformer rating, and adjusted the target price from $3.00 to $3.50.
Cronos Group Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Genfit SA (GNFT) and Cronos Group (CRON)
B of A Securities: Maintaining the Cronos Group (CRON.US) rating, adjusted from below the market to below the market rating, and adjusted the target price from $2.00 to $2.50.
Cronos Group Analyst Ratings
B of A Securities Maintains Underperform on Cronos Group, Raises Price Target to $2.5
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)
Jefferies Sticks to Its Hold Rating for Cronos Group (CRON)
Jefferies Keeps Their Hold Rating on Cronos Group (CRON)
Jefferies Sticks to Its Hold Rating for Cronos Group (CRON)
B of A Securities Maintains Underperform on Cronos Group, Raises Price Target to $2
Cronos Group Analyst Ratings
Cronos Group Sell Rating Affirmed Amid Modest Sales Forecasts and Competitive Challenges
Cronos Group (CRON) Gets a Hold From Jefferies
Jefferies Keeps Their Hold Rating on Cronos Group (CRON)
Positive Market Outlook and Financial Health: A Buy Rating for Cronos Group
Sell Rating on Cronos Group: Uncertainty in Profitability and Regulatory Changes Overshadowing Robust Sales Performance